Publications

Back to Publications

Stay up to date with our literature reviews which are curated by experts to feature the most important publications released each month. Explore our publications for access to concise summary slides for your own use.

Dapagliflozin and New-Onset Type 2 Diabetes in Patients With Chronic Kidney Disease Or Heart Failure: Pooled Analysis of the DAPA-CKD and DAPA-HF Trials

Lancet Diabetes Endocrinol 2022;10:24–34 doi.org/10.1016/

Participants with chronic kidney disease and heart failure without a reduction in HbA1c had a lower incidence of new-onset type 2 diabetes following treatment with dapagliflozin. Participants with no type 2 diabetes at baseline generally tolerated dapagliflozin.


LinkedIn